OBX (Obsidian Therapeutics) Other Long-Term Liabilities: $338.03 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBX Obsidian Therapeutics Inc OBX
8 GF Score
Price $27.50
View Full Analysis

What is Obsidian Therapeutics Other Long-Term Liabilities?

Obsidian Therapeutics OBX -1.79% 8 Other Long-Term Liabilities is $338.03 Mil as of Dec. 2025. GuruFocus rates OBX with a GF Score™ of 8/100.

Obsidian Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2025 was $338.03 Mil.

Obsidian Therapeutics's quarterly other long-term liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($338.23 Mil) but then declined from Dec. 2024 ($338.23 Mil) to Dec. 2025 ($338.03 Mil).

Obsidian Therapeutics's annual other long-term liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($338.23 Mil) but then declined from Dec. 2024 ($338.23 Mil) to Dec. 2025 ($338.03 Mil).

Obsidian Therapeutics Other Long-Term Liabilities Related Terms

Obsidian Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Obsidian Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Obsidian Therapeutics Other Long-Term Liabilities Chart

Obsidian Therapeutics Annual Data
Trend Dec24 Dec25
Other Long-Term Liabilities
338.23 338.03

Obsidian Therapeutics Semi-Annual Data
Dec24 Dec25
Other Long-Term Liabilities 338.23 338.03
OBX
8GF Score
Obsidian Therapeutics Inc OBX
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Obsidian Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $338.03 Mil mean?
Obsidian Therapeutics (OBX) has a Other Long-Term Liabilities of $338.03 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Obsidian Therapeutics and its competitors.
Is Obsidian Therapeutics' Other Long-Term Liabilities too high?
Obsidian Therapeutics' current Other Long-Term Liabilities is $338.03 Mil. Overall, Obsidian Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' Other Long-Term Liabilities compare to ?
Obsidian Therapeutics' Other Long-Term Liabilities of $338.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Obsidian Therapeutics and its competitors. Obsidian Therapeutics's current Other Long-Term Liabilities is $338.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current Other Long-Term Liabilities of $338.03 Mil. The current Other Long-Term Liabilities is $338.03 Mil. Obsidian Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current Other Long-Term Liabilities is $338.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Obsidian Therapeutics Business Description

Comparable Companies
Address 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
8GF Score

Get the complete analysis for OBX

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.50
Price